What if a simple blood test could help us decide when to switch treatments in advanced melanoma? 🧬 Join OncoAlert & our Faculty Dr. Mario Balsa🇪🇸 for this #WeekinOncology #Melanoma as he discusses how the CAcTUS🌵 trial explores how circulating tumour DNA (ctDNA) could help personalise treatment sequencing for patients with BRAF-mutant melanoma—potentially allowing clinicians to make faster, data-driven decisions. Use of circulating tumour DNA to prospectively guide a switch from targeted to immune therapy in BRAF mutant advanced melanoma: the randomised phase II CAcTUS trial The CAcTUS phase II trial explored whether circulating tumour DNA (ctDNA) could guide treatment sequencing in patients with BRAF-mutant advanced melanoma. Patients received targeted therapy (TT) or checkpoint inhibitor immunotherapy (CPI), with treatment switching based on progression or an 80% reduction in BRAF variant allele frequency. ctDNA results were delivered rapidly, successfully guiding treatment decisions. Findings suggest ctDNA may identify treatment response early and help optimise sequencing, with no new safety concerns observed. buff.ly/x6xm9Mh @BeckiLee
@DrHMShaw
@DamianMullan2
@FlorentMouliere
@hitesh22mistry
@TurajlicLab 📣 Pinging our faculty: @nataliagandur @realbowtiedoc @FernandoOnco @ElisaAgostinett @to_be_elizabeth @MarioBalsaMD @BRicciutiMD @HHorinouchi @UOzkerim @p_ciracimd @AmandaNizamMD @scocmem @DrVilmaPBarcia @DraMartinezLago @DrMirallas @GIMedOnc @BettinaRyll 🎗️ Pinging colleagues in melanoma: @DrBetofMDPhD @FunchainMD @CureMelanoma @Melanoma_doctor @HTawbi_MDPhD @Chrystal_Paulos @JaniceM10 @ProfGLongMIA @ProfRAScolyer @JeffGershenwald @MelanomaAus @AIMatMelanoma